Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
暂无分享,去创建一个
M. Sehested | M. Jäättelä | S. Nielsen | P. B. Jensen | F. Björkling | Maxwell Sehested | Marja Jäättelä | Søren Jensby Nielsen | Peter Buhl Jensen | Fredrik Björkling | Uffe Høgh Olesen | Mette Knak Christensen | U. H. Olesen | M. Christensen
[1] G. Hageman,et al. Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. , 2005, Free radical biology & medicine.
[2] T. Dawson,et al. Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.
[3] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[4] L. de Leij,et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. , 1985, Cancer research.
[5] S. Imai,et al. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals , 2007, Current opinion in gastroenterology.
[6] E. Verdin,et al. Sirtuins: critical regulators at the crossroads between cancer and aging , 2007, Oncogene.
[7] Max Hasmann,et al. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.
[8] L. Binderup,et al. Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine. , 2000, Biochemical pharmacology.
[9] L. Binderup,et al. Novel cyanoguanidines with potent oral antitumour activity , 1997 .
[10] Mahasti Saghatchian,et al. Molecular targets and cancer therapeutics. , 2007, European journal of cancer.
[11] L. Binderup,et al. Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828 , 2004, Anti-cancer drugs.
[12] G. de Murcia,et al. The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[13] H. Hansen,et al. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. , 1993, British Journal of Cancer.
[14] J. Khan,et al. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.
[15] L. Guarente,et al. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. , 2006, Genes & development.
[16] R. Stierum,et al. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. , 2001, Mutation research.
[17] L. Binderup,et al. Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. , 2001, European journal of cancer.
[18] P. Pedersen. The cancer cell’s “power plants” as promising therapeutic targets: An overview , 2007, Journal of bioenergetics and biomembranes.
[19] R. Larsson,et al. Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. , 2001, Biochemical pharmacology.
[20] A. Bürkle,et al. Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions , 2004, International journal of cancer.
[21] R. Larsson,et al. The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro–from cytotoxic synergy to complete inhibition of apoptosis , 2002, British journal of pharmacology.
[22] M. Madsen,et al. Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activity , 2004, International Journal of Cancer.
[23] R. Larsson,et al. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. , 2002, Biochemical Pharmacology.
[24] David T. Smith. Niacin , 1943, Reactions Weekly.
[25] L. Binderup,et al. Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. , 2001, European journal of pharmacology.
[26] C. M. Hansen,et al. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. , 2000, Anticancer research.
[27] F H Dost,et al. Was ist Pharmakokinetik?* , 1967 .
[28] G. Poirier,et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.
[29] M. Karlsson,et al. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. , 2006, Anticancer research.
[30] R. Frye,et al. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. , 1999, Biochemical and biophysical research communications.
[31] T. Skov,et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.
[32] Chris Twelves,et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.
[33] L. Saltz,et al. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.
[34] M. Noda,et al. Enhancement of poly‐adenosine diphosphate‐ribosylation in human hepatocellular carcinoma , 2000, Journal of gastroenterology and hepatology.
[35] H. Hansen,et al. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. , 1993, Biochemical pharmacology.
[36] R. Larsson,et al. Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. , 2002, Anticancer research.